

**4<sup>th</sup> INTERNATIONAL CONFERENCE ON  
MULTIPLE MYELOMA**

Mandelieu, France

October 5-7, 2018

Chairs : Kenneth C. Anderson, Maria-Victoria Mateos, Philippe Moreau

**Friday, October 5, 2018**

**08:30–08:40 Welcome**

**SESSION I – Smoldering Myeloma**

**Chairs: Robert A. Kyle (Rochester)**

08:40-08:45	Introduction	Robert A. Kyle (Rochester)
08:45-09:00	From SMM to MM: Do all clones take the same road?	Madhav V. Dhodapkar (New York)
09:00-09:05	<i>Discussion</i>	
09:05-09:20	What are the current definitions of smoldering MM and of high-risk smoldering MM?	Irene Ghobrial (Boston)
09:20-09:25	<i>Discussion</i>	
09:25-09:40	How to monitor SMM (biology, clinical, imaging, MRD)	Ola Landgren (New York)
09:40-09:45	<i>Discussion</i>	
09:45-10:00	Recent results of clinical trials in SMM	Maria-Victoria Mateos (Salamanca)
10:00-10:05	<i>Discussion</i>	
10:05-10:35	<i>Round Table Panel Discussion or short communications</i>	

**10:35-11:00 Coffee Break**

**SESSION II – Diagnosis of multiple myeloma**

**Chair: Jesus San Miguel (Pamplona)**

11:00-11:05	Introduction	Jesus San Miguel (Pamplona)
11:05-11:20	Diagnostic criteria – Initial workup	Evangelos Terpos (Athens)
11:20-11:25	<i>Discussion</i>	
11:25-11:40	Genetics and risk assessment (including clonal evolution and clinical implications in terms of risk assessment)	Hervé Avet-Loiseau (Toulouse)
11:40-11:45	<i>Discussion</i>	
11:45-12:00	Plasma cell leukaemia – Extramedullary disease	Niels van de Donk (Amsterdam)
12:00-12:05	<i>Discussion</i>	
12:05-12:35	<i>Round Table or Panel Discussion or Short Communications or Controversial Debates</i>	

**12:35-14:15 Lunch**

**13:05-14:05 Satellite symposium (Takeda)**

**SESSION III – Frontline therapy in patients not eligible for ASCT**

**Chair: Thierry Facon (Lille)**

14:15-14:20	Introduction	Thierry Facon (Lille)
14:20-14:35	Geriatric assessment: is it required?	Alessandra Larocca (Turin)
14:35-14:40	<i>Discussion</i>	
14:40-14:55	European guidelines	Sonja Zweegman (Amsterdam)
14:55-15:00	<i>Discussion</i>	
15:00-15:15	American guidelines	Noopur Raje (Boston)
15:15-15:20	<i>Discussion</i>	

**16:20-16:50 Coffee break**

16:50-17:05	Ongoing trials And what about frontline treatment when new drugs are not available?	Kwee Yong (London)
17:05-17:10	<i>Discussion</i>	
17:10-17:50	<b>DEBATE: Continuous therapy or fixed duration?</b>	
17:10-17:25	Continuous therapy	Thierry Facon (Lille)
17:25-17:30	<i>Discussion</i>	
17:30-17:45	Fixed duration	Jesus San Miguel (Pamplona)
17:45-17:50	<i>Discussion</i>	

**SESSION IV – Frontline therapy in patients eligible for ASCT**

**Chair: Michele Cavo (Bologna)**

17:50-17:55	Introduction	Michele Cavo (Bologna)
17:55-18:10	European guidelines vs US guidelines	Paul Richardson (Boston)
18:10-18:15	<i>Discussion</i>	
18:15-18:30	Induction therapy: triplet, quadruplet?	Philippe Moreau (Nantes)
18:30-18:35	<i>Discussion</i>	
18:35-18:50	How to cure high risk patients	Pieter Sonneveld (Rotterdam)
18:50-18:55	<i>Discussion</i>	
18:55-19:35	<b>DEBATE: ASCT: Single or tandem</b>	
18:55-19:10	Single	Edward A. Stadtmauer (Philadelphia)
19:10-19:15	<i>Discussion</i>	
19:15-19:30	Tandem	Michele Cavo (Bologna)
19:30-19:35	<i>Discussion</i>	

**19:35 Get together and poster viewing (stand up cocktails and buffet dinner for all)**

## Saturday, October 6, 2018

### 08:30-10:00 Satellite symposium (Celgene)

#### 09:00-10:00 3 Simultaneous Meet the Expert sessions (non-clinical)

- |   |                                 |
|---|---------------------------------|
| 1. Genomics and epigenomic profile in myeloma         | Nikhil C. Munshi (Boston)*      |
| 2. Evaluation of immunotherapy                        | Madhav V. Dhodapkar (New York)* |
| 3. Current and future technologies for MRD assessment | Philippe Moreau (Nantes)*       |

#### 10:00-10:25 Coffee break

#### SESSION V – Assessment of response

Chair: Shaji Kumar (Rochester)

- |             |  |                           |
|-------------|--|---------------------------|
| 10:25-10:30 | Introduction   | Shaji Kumar (Rochester)   |
| 10:30-10:45 | Flow cytometry   | Ola Landgren (New York)   |
| 10:45-10:50 | <i>Discussion</i>  |                           |
| 10:50-11:05 | New generation sequencing                                      | Nikhil C. Munshi (Boston) |
| 11:05-11:10 | <i>Discussion</i>  |                           |
| 11:10-11:25 | PET/CT   | Elena Zamagni (Bologna)   |
| 11:25-11:30 | <i>Discussion</i>  |                           |
| 11:30-11:45 | Other imaging techniques                                       | Evangelos Terpos (Athens) |
| 11:45-11:50 | <i>Discussion</i>  |                           |
| 11:50-12:20 | <i>Round Table or Panel Discussion or Short Communications</i> |                           |

#### 12:20-14:00 Lunch

### 12:50-13:50 Satellite symposium (Janssen)

#### SESSION VI – Relapsed multiple myeloma

Chair: Paul Richardson (Boston)

- |             |   |                              |
|-------------|---|------------------------------|
| 14:00-14:05 | Introduction  | Paul Richardson (Boston)     |
| 14:05-14:25 | When and how to treat first relapse according to the guidelines | Meletios Dimopoulos (Athens) |
| 14:25-14:30 | <i>Discussion</i>   |                              |
| 14:30-14:50 | Sequencing therapies  | Heinz Ludwig (Vienna)        |
| 14:50-14:55 | <i>Discussion</i>   |                              |
| 14:55-15:10 | New drugs, new immune therapies, new targeted therapies         | Enrique Ocio (Salamanca)     |
| 15:10-15:15 | <i>Discussion</i>   |                              |
| 15:15-15:45 | <i>Round Table or Panel Discussion or Short Communications</i>  |                              |

23/01/2018

**15:45-16:15 Coffee break**

**SESSION VII – Immunotherapy**

**Chair: Kenneth C. Anderson (Boston)**

16:15-16:20	Introduction	Kenneth C. Anderson (Boston)
16:20-16:35	Monoclonal antibodies	Saad Usmani (Charlotte)
16:35-16:40	<i>Discussion</i>	
16:40-16:55	Adoptive cell therapy	Jesus Berdeja (Nashville)
16:55-17:00	<i>Discussion</i>	
17:00-17:15	Vaccines in myeloma	David Avigan (Boston)
17:15-17:20	<i>Discussion</i>	
17:20-17:35	Future combinations for the treatment of MM	Kenneth C. Anderson (Boston)
17:35-17:40	<i>Discussion</i>	
17:40-18:10	<i>Round Table or Panel Discussion or Short Communications</i>	

**18:30-19:30 Satellite symposium (Amgen – To be confirmed)**

**Sunday, October 7, 2018**

**07:30-8:30 Simultaneous Breakfast Meet the Expert Sessions (Clinical)**

1. New immunotherapies	Edward A. Stadtmauer (Philadelphia)*
2. Evolving role of stem cell transplantation	Peter Sonneveld (Rotterdam)*
3. Incorporating MRD assessment in the routine practice	Hervé Avet-Loiseau (Toulouse)*

**SESSION VIII – Data management issues**

**Chair: Jean-Luc Harousseau (Nantes)\***

08:35-08:40	Introduction	Jean-Luc Harousseau (Nantes)*
08:40-08:55	How to judge the value of a clinical trial: HR, median PFS, p-value	Robert Hills (Cardiff)
08:55-09:00	<i>Discussion</i>	
09:00-09:15	New end-point and new designs of clinical trials	Shaji Kumar (Rochester)
09:15-09:20	<i>Discussion</i>	
09:20-09:35	Real-world evidence –What is it and what can it tell us?	Kwee Yong (London)
09:35-09:40	<i>Discussion</i>	
09:40-09:55	Optimal cost/safety/efficacy/QOL ration	Jean-Luc Harousseau (Nantes)
09:55-10:00	<i>Discussion</i>	
10:00-10:30	<i>Round Table or Panel Discussion or Short Communications</i>	

23/01/2018

**10:30-10:50** *Coffee break*

**SESSION IX – Other plasma cell disorders**

**Chair: Giampaolo Merlini (Pavia)\***

10:50-10:55	Introduction	Giampaolo Merlini (Pavia)*
10:55-11:10	Waldeström macroglobulinemia	Steven Treon (Boston)
11:10-11:15	<i>Discussion</i>	
11:15-11:30	Amyloidosis	Giampaolo Merlini (Pavia)
11:30-11:35	<i>Discussion</i>	
11:35-11:50	MGUS with systemic manifestations	Jean-Paul Fermand (Paris)
11:50-11:55	<i>Discussion</i>	
11:55-12:10	POEMS syndrome	Arnaud Jaccard (Limoges)
12:10-12:15	<i>Discussion</i>	
12:15-12:30	Light chain MGUS/SMM: are different entities?	Jean-Paul Fermand (Paris)
12:30-12:35	<i>Discussion</i>	
12:35-13:05	<i>Round Table or Panel Discussion or Short Communications</i>	

**13:05-13:10** *Closing Remarks*

**MEETING CLOSURE**

*\*Pending confirmation*